Fibrin Modulating Agents

Name
Fibrin Modulating Agents
Accession Number
DBCAT000011
Description

Agents that affect the function of FIBRIN in BLOOD COAGULATION. They used as COAGULANTS for HEMORRHAGE or ANTICOAGULANTS for THROMBOSIS.

Drugs
DrugDrug Description
LepirudinA protein-based direct thrombin inhibitor used to reverse and prevent thrombus formation in heparin-induced thrombocytopenia.
AlteplaseA recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
ReteplaseA purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
AnistreplaseA form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
TenecteplaseA modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
StreptokinaseA purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.
MenadioneThe primary known function of vitamin K is to assist in the normal clotting of blood, but it may also play a role in normal bone calcification.
TiclopidineA platelet aggregation inhibitor used in the prevention of conditions associated with thrombi, such as stroke and transient ischemic attacks (TIA).
AnagrelideA platelet-reducing agent used in myeloproliferative disorders to prevent thrombotic complications.
Tranexamic acidAn antifibrinolytic agent used for heavy menstrual bleeding.
ArdeparinFor prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.
Aminocaproic acidAn antifibrinolytic agent used to induce clotting postoperatively.
TirofibanA platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome.
PhylloquinoneA fat soluble vitamin used to treat hemorrhagic conditions in infants and coumarin overdoses.
HeparinAn anticoagulant indicated for thromboprophylaxis and to treat thrombosis associated with a variety of conditions such as pulmonary embolism and atrial fibrillation.
CilostazolAn antiplatelet agent and vasodilator used for the symptomatic relief of intermittent claudication.
EnoxaparinA low molecular weight heparin used for the prophylaxis of deep vein thrombosis and ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.
DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DefibrotideA mixture of single-stranded oligonucleotides used in the treatment of severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.
AncrodAn anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country.
FibrinolysinFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
Pentaerythritol tetranitrateUsed for the treatment of angina pectoris .
SulodexideSulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated...
DanaparoidA heparinoid with anticoagulant and antithrombotic activities used for the treatment of acute episode of Heparin-Induced Thrombocytopenia (HIT), and for prophylaxis in patients with a history of HIT.
DalteparinA low molecular weight heparin used for the prophylaxis of thrombotic events in certain patients and prevent acute cardiac ischemic events in patients with unstable angina and non-Q-wave myocardial infarction.
TinzaparinA low molecular weight heparin used for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin.
NadroparinA low molecular weight heparin used for the prophylaxis of thrombotic events and deep vein thrombosis, and prevent unstable angina and non-Q-wave myocardial infarction.
BatroxobinNo approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously.
ReviparinBy the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients. It is also indicated for the long-term treatment of...
DesirudinIndicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
OzagrelOzagrel has been used in trials studying the treatment of Dry Eye Syndromes.
SarpogrelateSarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.
NitroaspirinNitroaspirin has been investigated for the treatment of Intermittent Claudication.
HigenamineHigenamine is under investigation in clinical trial NCT01451229 (Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects).
BrinaseNot Annotated
SaruplaseNot Annotated
FondaparinuxAn anticoagulant used to prevent venous thromboembolism, to treat deep vein thrombosis, and to improve survival following myocardial infarction.
EplivanserinEplivanserin has been used in trials studying the treatment of Sleep, Insomnia, Chronic Pain, Fibromyalgia, and Primary Insomnia, among others.
Menaquinone 6Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different Dosages Vitamin K2).
MenaquinoneMenaquinone is under investigation in clinical trial NCT01533441 (Vitamin K2 Intervention in Patients With Vitamin K Antagonists).
SemuloparinInvestigated for use/treatment in thrombosis.
ParnaparinUsed in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.
MonteplaseMonteplase has been used in trials studying the treatment of Pulmonary Embolism.
Drugs & Drug Targets
DrugTargetType
LepirudinProthrombintarget
AlteplaseUrokinase plasminogen activator surface receptortarget
AlteplaseFibrinogen alpha chaintarget
AlteplasePlasminogentarget
AlteplasePlasminogen activator inhibitor 1target
ReteplaseFibrinogen alpha chaintarget
ReteplasePlasminogentarget
ReteplasePlasminogen activator inhibitor 1target
AnistreplaseFibrinogen alpha chaintarget
AnistreplasePlasminogentarget
AnistreplasePlasminogen activator inhibitor 1target
TenecteplaseUrokinase plasminogen activator surface receptortarget
TenecteplasePlasminogen activator inhibitor 1target
TenecteplaseFibrinogen alpha chaintarget
TenecteplasePlasminogen activator inhibitor 2target
TenecteplaseTetranectintarget
TenecteplaseKeratin, type II cytoskeletal 8target
TenecteplaseAnnexin A2target
TenecteplaseCalreticulintarget
TenecteplaseCalnexintarget
TenecteplaseProlow-density lipoprotein receptor-related protein 1target
TenecteplasePlasminogentarget
StreptokinasePlasminogentarget
StreptokinaseProteinase-activated receptor 1target
StreptokinaseCytosolic phospholipase A2enzyme
MenadioneProthrombintarget
MenadioneVitamin K epoxide reductase complex subunit 1target
MenadioneCoagulation factor IXtarget
MenadioneVitamin K-dependent gamma-carboxylasetarget
MenadioneVitamin K-dependent protein Ctarget
MenadioneVitamin K-dependent protein Starget
MenadioneNAD(P)H dehydrogenase [quinone] 1target
MenadioneRibosyldihydronicotinamide dehydrogenase [quinone]target
MenadioneVitamin K epoxide reductase complex subunit 1-like protein 1target
MenadioneXanthine dehydrogenase/oxidaseenzyme
MenadioneAldehyde oxidaseenzyme
MenadioneMethylenetetrahydrofolate reductaseenzyme
MenadioneCytochrome P450 1A1enzyme
MenadioneOsteocalcintarget
MenadioneCytochrome P450 1A2enzyme
MenadioneCytochrome P450 2A6enzyme
TiclopidineP2Y purinoceptor 12target
TiclopidineCytochrome P450 2C19enzyme
TiclopidineCytochrome P450 2B6enzyme
TiclopidineCytochrome P450 2C9enzyme
TiclopidineCytochrome P450 2D6enzyme
TiclopidineMyeloperoxidaseenzyme
TiclopidineCytochrome P450 1A2enzyme
TiclopidineCytochrome P450 2C8enzyme
TiclopidineCytochrome P450 2E1enzyme
AnagrelidecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
AnagrelideCytochrome P450 1A2enzyme
Tranexamic acidPlasminogentarget
Tranexamic acidSolute carrier family 15 member 2transporter
ArdeparinHeparin cofactor 2target
ArdeparinAntithrombin-IIItarget
Aminocaproic acidPlasminogentarget
Aminocaproic acidTissue-type plasminogen activatortarget
Aminocaproic acidApolipoprotein(a)target
Aminocaproic acidAldehyde oxidaseenzyme
TirofibanIntegrin alpha-IIbtarget
TirofibanIntegrin beta-3target
PhylloquinoneVitamin K-dependent gamma-carboxylasetarget
PhylloquinoneOsteocalcintarget
HeparinAntithrombin-IIItarget
HeparinCoagulation factor Xtarget
HeparinP-selectintarget
HeparinHeparanaseenzyme
HeparinFibroblast growth factor receptor 4target
HeparinFibroblast growth factor 4target
HeparinFibroblast growth factor 19target
HeparinFibroblast growth factor receptor 1target
HeparinFibroblast growth factor 1target
HeparinFibroblast growth factor receptor 2target
HeparinFibroblast growth factor 2target
HeparinPlatelet factor 4target
HeparinHepatocyte growth factortarget
HeparinThyroxine-binding globulincarrier
CilostazolcGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
CilostazolCytochrome P450 2C19enzyme
CilostazolCytochrome P450 3A4enzyme
CilostazolCytochrome P450 3A5enzyme
CilostazolCytochrome P450 3A7enzyme
CilostazolCytochrome P450 1A2enzyme
CilostazolCytochrome P450 2D6enzyme
EnoxaparinAntithrombin-IIItarget
EnoxaparinCoagulation factor Xtarget
EnoxaparinMyeloperoxidaseenzyme
DesmoteplasePlasminogentarget
DefibrotideAdenosine receptor A1target
DefibrotideAdenosine receptor A2atarget
DefibrotideAdenosine receptor A2btarget
AncrodFibrinogen alpha chaintarget
FibrinolysinPlasminogen activator inhibitor 1target
FibrinolysinUrokinase-type plasminogen activatortarget
Pentaerythritol tetranitrateHemoglobin subunit alphatarget
Pentaerythritol tetranitrateHemoglobin subunit betatarget
Pentaerythritol tetranitrateGuanylate cyclase soluble subunit alpha-2enzyme
Pentaerythritol tetranitrateFree radicalstarget
Pentaerythritol tetranitrateNitric oxide synthase, endothelialenzyme
Pentaerythritol tetranitrateAldehyde dehydrogenase, mitochondrialenzyme
SulodexideHeparin cofactor 2target
SulodexideAntithrombin-IIItarget
DanaparoidAntithrombin-IIItarget
DalteparinVascular endothelial growth factor Atarget
DalteparinTissue factor pathway inhibitortarget
DalteparinHeparanaseenzyme
DalteparinAntithrombin-IIItarget
DalteparinP-selectintarget
TinzaparinAntithrombin-IIItarget
TinzaparinA disintegrin and metalloproteinase with thrombospondin motifs 4enzyme
TinzaparinIntegrin alpha-4target
TinzaparinStromal cell-derived factor 1target
NadroparinProto-oncogene c-Fostarget
NadroparinMyc proto-oncogene proteintarget
NadroparinP-selectintarget
NadroparinAntithrombin-IIItarget
DesirudinCarboxypeptidase A1enzyme
Protein CCoagulation factor Vtarget
Protein CCoagulation factor VIIItarget
Sarpogrelate5-hydroxytryptamine receptor 2Ctarget
Sarpogrelate5-hydroxytryptamine receptor 2Atarget
NitroaspirinProstaglandin G/H synthase 1target
FondaparinuxAntithrombin-IIItarget
FondaparinuxCoagulation factor Xtarget
Eplivanserin5-hydroxytryptamine receptor 2Atarget
Eplivanserin5-hydroxytryptamine receptor 2Ctarget